课题基金 / 基金详情

Establish mentofthe minimally invasive treatments based on biological characteristics for advanceduro logical cancers.

Establish mentofthe minimally invasive treatments based on biological characteristics for advanceduro logical cancers.
建立基于晚期泌尿系统癌症生物学特性的微创治疗方法。
批准号:
07407046
负责人:
TACHIBANA Masaaki
金额:
$14.21万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (A)
财政年份:
1995
资助国家:
日本
项目状态:
已结题
起止时间:
1995 至 1997

项目摘要

项目成果

TACHIBANA Masaaki的其他基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
This study was designed to determine the biological characteristics which reflect invasiveness and malignant potential of urological cancers and try to establish new therapeutic modalities as minimally invasive organ preserving treatments. Flow cytometric DNA ploidy analysis for human bladder cancers may provide significant diagnostic and prognostic potential. Combined use of histological and flow cytometric parameters may offer additional information regarding the clinical outcome for bladder cancer patients. We also studied the loss of heterogygosity (LOH) of the multiple chromosome regions as possible suppressor gene abnormalities on human bladder cancers and their relation ships with clinical outcomes. High-grade and aggressive tumors contain multiple suppressor gene alterations that demonstrate a greater genetic instability. Therefore, a microsatellite analysis of a variety of susceptible suppressor gene regions is considered to be useful in determining both the therapeutic strate … More gies and prognostic factors for patients with bladder cancer. Considerable attention has been given to combination chemotherapy for the treatment of advanced bladder cancer. However, the effectiveness of this chemotherapy remains less than satisfactory. The key to enhancing the efficacy of this treatment lies in ascertaining the proliferating activities of cancer cells composing target tumor tissue and in being able to gauge the response to antitumor agents of cancer cells. It is convincing that there are different efficacies following a variation in multidrug treatment depending on its scheduling. In the present study, emphasis was placed on determining the optimal time schedule of combination chemotherapy administered against bladder cancer cells using an analysis of cell kinetic characteristics of the chemotherapeutic agents. Methotrexate (MTX) pretreatment can significantly enhance the antitumor effects of vinblastine (VBL) and etopocide (EP) when compared with simultaneous treatment and/or the reversed schedule in combined chemotherapy with MTX and EP/VBL against bladder cancer cells, with induction of significant apoptosis. Nuclear factor kappa B (NF-kB) is one of the transcription factors which regulate cytokine gene expression and it was very recently shown to be a regulatory factor for the induction of apoptosis. In the present study, we determined that the growth of sytokine producing tumors was regulated by NF-kB and therefore the inhibition of NF-kB by adenovirus vector can be used as an effective gene therapy for the treatment of cytokine producing bladder cancer associated paraneoplastic syndromes. Melanoma antigen (MAGE) is known as a tumor rejection antigen cloned originally from malignant melanoma. MAGE has recently attracted great attention in cancer immunotherapy, especially regarding the induction of tumor specific cytotoxic T-cells (CTL) because it is widely expressed in various tumors but not in normal cells except for the testis and placenta.Additionally, we investigated whether or not growth and apoptosis can be regulated by NF-kB on TNF-alpha-resistant prostate cancer cells. NFkB activation prevents TNF-alpha-induced cell death in DU-145 and PC-3 cells. As a result, the inhibition of NF-kB activation may thus be an effective therapy for TNF-alpha-resistant prostate cancer cells. Less
期刊论文(30)
专著(0)
科研奖励(0)
会议论文
Tachibana M: "Prognostic significance of flow cytometric deoxyribonucleic acid analysis for patients with superficial bladder cancers" Cancer Detec Prev. in press
Tachibana M:“流式细胞仪脱氧核糖核酸分析对浅表性膀胱癌患者的预后意义”Cancer Detec Prev。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Jun Nakashima et al.: "The value of serum carboxyterminal propeptide of type 1 procollagen in predicting Bone Metastases in prostate cancer." J.Urol.(in press).
Jun Nakashima 等人:“1 型前胶原血清羧基末端前肽在预测前列腺癌骨转移中的价值。”
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Tachibana M: "Role of proliferative activity estimated by bromodeoxyuridine labeling indexin determining predictive factors of recurrence in superficial intermediately malignant bladder tumors." J Urol. 156(10). 63-63 (1996)
Tachibana M:“通过溴脱氧尿苷标记指数估计的增殖活性在确定浅表中度恶性膀胱肿瘤复发的预测因素中的作用。”
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
30
    Tumor specific immunotherapy using dendritic cells generated from allogeneic peripheral stem cell.
    • 批准号:
      14370520
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $9.22万
    • 财政年份:
      2002
    • 负责人:
      TACHIBANA Masaaki
    • 依托单位:
    HLA restricted tumor specific antigen epitope pulsed autologous dendritic cell vaccine treatment for hormone refractory prostate cancer
    • 批准号:
      12671557
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $2.56万
    • 财政年份:
      2000
    • 负责人:
      TACHIBANA Masaaki
    • 依托单位:
    Induction of apoptosis against cytokine-producing urological cancer
    • 批准号:
      10671493
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $2.11万
    • 财政年份:
      1998
    • 负责人:
      TACHIBANA Masaaki
    • 依托单位:
    Studies on objective indicator for predicting malignant potential of bladder cancer.
    • 批准号:
      04454409
    • 项目类别:
      Grant-in-Aid for General Scientific Research (B)
    • 资助金额:
      $3.9万
    • 财政年份:
      1992
    • 负责人:
      TACHIBANA Masaaki
    • 依托单位: